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Background/aim: Central line-associated bloodstream infections (CLABSIs) are associated with substantial morbidity and mortality
and the infection rates vary in a wide range (high: 62.5%; low: 20%) in developing countries. We aimed to investigate the characteristics
and the risk factors for mortality in patients with CLABSIs in intensive care units (ICUs) and provide the relevant data.
Materials and methods: The electronic medical records database and file records obtained through active surveillance by an infection
control committee of a hospital were screened to identify patients with CLABSIs hospitalized from January 2008 through July 2013.
Results: A total of 166 CLABSI episodes in 158 patients out of 17,553 on 38,562 catheter and 94,512 hospitalization days were evaluated.
The infection developed in catheterized patients at a median of 14 days (range 2–88), and the highest infection rate with 13.4% (n = 20)
was the femoral region among the places where the catheter was inserted. Of the patients catheterized, 54.4% survived whereas 45.6%
died. In patients having Candida infection, the mortality was significantly higher. High APACHE II scores and Candida infections were
found to be significant risk factors associated with mortality.
Conclusion: APACHE II scores and bloodstream infection with Candida species were the most powerful predictors of mortality. In ICU
practice, health-care givers must consider the emerging role of Candida for both invasiveness and mortality.
Key words: Intensive care unit, central line-associated bloodstream infections, nosocomial infection, mortality

1. Introduction
Central venous catheters (CVCs) are an essential part
of care for critically ill patients, especially for those in
intensive care units (ICUs). Patients in ICUs are more
vulnerable to nosocomial infections compared to those
in other wards of the hospital. As a routine intensive
care practice, vascular access carries some potential
risks, especially for bloodstream infections (1). Nearly
60% of nosocomial bacteremia has been reported to
originate from vascular procedures (2). Besides their
help for therapy, the use of CVCs can be associated with
life-threatening infections (3). Central line-associated
blood stream infections (CLABSIs) are associated with
substantial morbidity and mortality (4). A recent survey
from the United States reported more than 250,000
vascular catheter associated bacteremias and fungemias
detected annually with a mortality rate of 12%–25% in
critically ill patients (5,6). The reported mortality rates in
developing countries have wide ranges as high as 62.5%
and as low as 20% (1,7).
* Correspondence: aynur.atilla@gmail.com
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The main aim of the present study was to investigate the
characteristics and the risk factors for mortality in patients
with CLABSIs in ICUs and provide the relevant data.
2. Materials and methods
This study was conducted in Samsun Education and
Training Hospital, a 620-bed hospital with 84 ICU beds.
It is a tertiary reference hospital with a total of 62 beds for
tertiary level care and the rest for primary level care. Of the
62 beds, 22 beds are allocated to the medical ICU, 22 beds
are for the surgical ICU, 5 beds are for the cardiovascular
surgery ICU, and 13 beds are for the burn care center.
Tertiary level ICUs are units capable of providing complex,
multisystem life support for an indefinite period and
providing mechanical ventilation, extracorporeal renal
support services, and invasive cardiovascular monitoring
for an indefinite period. Primary level ICUs provide basic
multisystem life support usually for shorter periods.
However, our primary level ICU is not equipped to provide
mechanical ventilation.
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The electronic medical records database and file records
obtained through active surveillance of the infection
control committee were evaluated to identify patients
with CLABSIs hospitalized from January 2008 through
July 2013. CLABSIs were defined in patients who had
clinical signs of infection, as culture growth of the same
bacteria from the blood taken from peripheral veins and
catheter tip or blood taken from the catheter in patients
who did not have a source of infection other than catheter
origin. CLABSIs were recorded according to Center for
Disease Control definitions (8). Patients who had another
focus of infection were excluded the study. The Acute
Physiology and Chronic Health Evaluation (APACHE) II
scoring system was used to evaluate the disease severity
during the hospitalization in the ICU (9). Patient age, sex,
hospitalization period, underlying diseases, operations,
total parenteral nutrition, blood products used, the
hospitalization and the central venous catheter days
infection arose, localization of catheter, mortality status,
albumin level, microorganisms, and culture sensitivities
were recorded.
The bacteriological isolation and antibiotic
susceptibility tests were evaluated using the Phoenix 100
BD automated system (Becton Dickinson Diagnostic
Systems) according to Clinical and Laboratory Standards
Institute criteria (CLSI) (10). Blood cultures taken from
catheter and peripheral veins were evaluated using a
BACTEC 9050 (Becton Dickinson, ABD) automated
device. Typing of Candida species was performed by
germ-tube test.
Multidrug resistance (MDR) was deﬁned as
isolates resistant to at least three drugs in the following
classes: β-lactams, carbapenems, aminoglycosides, and
ﬂuoroquinolones. Extensive drug resistance (XDR) was
defined as nonsusceptibility to at least one agent in all but
two or fewer antimicrobial categories (i.e. bacterial isolates
remain susceptible to only one or two categories). Pandrug
resistance (PDR) was defined as nonsusceptibility to all
agents in all antimicrobial categories (i.e. no agents tested
as susceptible for that organism) (11).
2.1. Data analysis
Rates of invasive device use were calculated as total
days invasive device used divided by the total days of
hospitalization. The rates of device-related infections
were calculated by dividing the number of device-related
infections by the total number of days that the device was
used in the study population as described by the National
Healthcare Safety Network (NHSN) (12).
2.2. Statistical analysis
The data were analyzed using SPSS 17.0 and given as
numerical (%) and median (min–max). Logistic regression
analysis was used to predict risk and the chi-square test was
used in comparison of categorical variables. The Mann-

Whitney U test was used to compare both groups with
data that do not represent normal distribution. A P-value
of less than 0.05 was considered statistically significant.
3. Results
This study included a total of 166 episodes of CLABSIs from
158 patients on 38,562 catheter and 94,512 hospitalization
days in 17,553 patients that were hospitalized in ICUs
between January 2008 and July 2013. Of the patients, 86
(54%) were male [mean age 67 ± 17 years (median: 72; 16–
92), median hospitalization period 43 days (range, 5–287),
and median hospitalization period prior to CLABSI was
25 days (range, 3–278)]. CLABSIs developed after the 10th
catheter day in 65% (n = 108) of the patients. The median
catheter day for infection was 14 days (range: 2–88), and
the main region where the catheter was inserted was the
femoral region in 13.4% (n = 20). Of the patients, 78%
underwent endotracheal intubation and mechanical
ventilation. Total parenteral nutrition and blood and
blood products were given to 123 (78%) and 136 (86%)
patients, respectively. According to the APACHE II score,
disease severity during hospitalization was mean 25 ± 8
(median: 26; 6–45).
Of the patients, 86 (54.4%) survived whereas 72
(45.6%) died. Survivors and nonsurvivors were compared
considering several parameters (Table). The female/male
ratio was 32/54 and 40/32 for survivors and nonsurvivors,
respectively, with a significant difference (P < 0.05).
Albumin levels were significantly lower in nonsurvivors.
The comparison of other parameters is shown in the
Table. Forty-four patients had Acinetobacter baumanni
infections and of them 15 (34%) died. Of the 35 patients
with Candida infection, 24 died (68.5%) (P < 0.01).
Approximately one-third of patients died before blood
cultures were obtained. Antifungal therapy was initiated
in 3.1 ± 1.9 days (median: 3; 1–10). The mortality rates
were not significantly different between the patients. The
catheter removal rate was significantly lower in patients
who died (P < 0.001). No significant differences were
found considering mortality in patients infected with
Acinetobacter. However, the mortality was significantly
higher in patients having Candida infection (P < 0.01).
Logistic regression analysis showed that APACHE level II
and Candida infection were the risk factors for mortality
(Table).
3.1. Incidence of infection
The CLABSI rate in ICUs was 2–8 per 1000 catheter days
between 2008 and 2013. The mean was 5.6 (5–7.2) in the
medical ICU, 5 (2.5–8.08) in the surgical ICU, 2.45 (0–5.56)
in the primary level ICU, 0.23 (0–1.3) in the cardiovascular
ICU, and 2.83 (0–7.04) in the burn care unit per 1000
catheter days. CLABSI rate by years is shown in Figure
1. The catheter utilization rate was 13% (8%–21%) in the
burn care unit, 18% (6%–25%) in the primary level ICU,
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Table. Patients’ characteristics and risk factors of survivors and nonsurvivors.
Total

Survivors

Nonsurvivors

n (%)

n (%)

n (%)

Age (years) (mean ± SD)

67 ± 17

65 ± 17

68 ± 18

>0.05

Female

72 (46%)

32 (37%)

40 (57%)

<0.05

Comorbidity

106 (64%)

54 (59%)

52 (70%)

>0.05

Diabetes mellitus

53 (34%)

29 (34%)

24 (33%)

Neurological disease

29 (18%)

17 (20%)

12 (17%)

Malignancy

16 (10%)

6 (7%)

10 (14%)

Trauma

26 (16.5%)

16 (19%)

10 (14 %)

>0.05

Surgery

42 (26%)

24 (28%)

17 (24%)

>0.05

Albumin (g/dL) (mean ± SD)

2.4 ± 0.4

2.5 ± 0.5

2.3 ± 0.4

APACHE II (mean ± SD)

26 ± 7.6

24 ± 7.7

28 ± 7

Endotracheal intubation

129 (78%)

66 (72%)

63 (85%)

Gram negative

91 (55%)

58 (63%)

33 (45%)

Gram positive

40 (24%)

23 (25%)

17 (23%)

Candida spp.

35 (21%)

11 (12%)

24 (32%)

MDR, gram negative

73 (81%)

44 (77%)

29 (88%)

<0.05

Acinetobacter infected

44 (26.5%)

29 (32%)

15 (20%)

>0.05

After the 10th catheter day

108 (65.1%)

60 (65.2%)

48 (64.9)

>0.05

Median
(Min–Max)

Median
(Min–Max)

Median
(Min–Max)

P

Length of stay prior infection

24 (3–278)

26 (3–175)

21 (5–278)

>0.05

Length of stay

43 (5–287)

56 (5–287)

29 (7–287)

<0.001

Catheter day

14 (2–88)

14 (3–88)

14 (2–64)

>0.05

Variables

P

Logistic regression
Odds ratio

95% Cl

P

0.51

0.26–1.01

0.05

<0.01

0.53

0.24–1.15

0.11

<0.001

1.1

1.02–1.13

0.004

<0.05

1.72

0.69–4.25

0.23

3.4

1.51–7.53

0.003

>0.05

Etiology
<0.01

ICU: Intensive care unit, MDR: Multidrug resistant.

58% (24%–0%) in the medical ICU, 64% (37%–76%) in the
surgical ICU, and 73% (59%–92%) in the cardiovascular
ICU.
3.2. Microorganisms and antibiotic resistance
Of all the isolates, 52% were gram negative, 27% gram
positive, and 21% were Candida spp. Thirty percent of all
Candida isolates were Candida albicans. Analysis by years
revealed the most frequent microorganisms as follows: A.
baumannii (n = 2, 28.5%) and Staphylococcus spp. (n = 2,
28.5%) in 2008, A. baumannii (n = 4, 28.6%) and Candida
spp. (n = 4, 28.6%) in 2009, A. baumannii (n = 12, 50%) in
2010, Candida spp. (n = 15, 30%) in 2011, A. baumannii
(n = 13, 23.2%) in 2012, and Klebsiella pneumoniae (n = 7,
32%) in 2013 (Figure 2). Of all causative microorganisms,
3.5% were polymicrobial.
A total of 172 bacterial isolates were obtained. The
most predominant bacterial isolate was A. baumannii (n
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= 45, 26%), followed by Candida spp. (n = 37, 21.4%),
Staphylococcus spp. (n = 25, 14.5%), Enterococcus spp.
(n = 21, 12.1%), K. pneumoniae (n = 23, 13.2%), and
Pseudomonas aeruginosa (n = 5, 2.8%). Of the gramnegative microorganisms 81% were MDR, 55% XDR,
and 1.1% PDR. K. pneumoniae demonstrated 54.5%
extended spectrum β lactamase (ESBL) and 4.2%
carbapenem resistance. All A. baumannii isolates
were multidrug resistant to Acinetobacter isolates.
Thirty-nine had XDR (86.6%), whereas one isolate
had PDR (2.2%). Carbapenem resistance was 91% in
A. baumannii. Methicillin resistant S. aureus (MRSA)
was as 66.7%, whereas the rate of methicillin resistant
coagulase negative staphylococcus (MR-CNS) was
100%. Vancomycin resistant Enterococcus spp. was as
9.5%. Coagulase negative staphylococcus included S.
epidermidis and S. haemolyticus.
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Figure 1. CLABSI rate by years. CLABSI: Central line-associated bloodstream infection, ICU:
intensive care unit, CVS-ICU: Cardiovascular surgery ICU.
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Figure 2. Distribution of microorganisms over 6 years.

4. Discussion
Although estimates for the incidence of CLABSI have
varied, data from the United States indicated 80,000
catheter-related bloodstream infections due to use of
central venous catheters with 15 million CVC days in
ICUs each year (13). The NHSN system report gives some
data about the rate of CLABSI in medical/surgical ICUs in
2012, which is pooled mean rates 1.2 (range 0–3) per 1000
catheter days (14). Rosenthal et al. reported the results
of 55 ICUs in 8 developing countries in which CLABSIs
comprised 30% of all device-associated infections or
12.5 cases (range 7.8–18.5 cases) per 1000 catheter days
(15). Peng et al. from China reported that the mean rate
of CLABSIs was 11.0 per 1000 central catheter days with
a catheter utilization rate of 72.8% (16). We found the
CLABSI rate in the medical ICU to be 5.6 (5–7.2) and 5
(2.5–8.08) in the surgical ICU per 1000 central catheter
days. This was considered somewhat higher compared
to the rates of developed countries, but it was considered
reasonable in developing countries. A brief explanation

for these higher rates may be our deficiencies in maximum
barrier precautions, inadequacy of nurses per patient
in ICUs, increased rates of catheter use, and the longer
periods of hospitalization.
We found that, of all isolates, 52% were gram negative
and the most predominant bacterial isolate was A.
baumannii followed by Candida spp. This was a different
causative microbiological profile from the others observed
in the past in which gram-positive microorganisms
displayed dominance. Likewise, some institutions have
observed an increase in catheter-associated infection
caused by gram-negative bacilli (17). The past decade
has witnessed an increasing occurrence of CLABSI
caused by multiple resistant gram-negative rods, most
notably A. baumannii (18). On the other hand, a recent
multicenter Brazilian study showed that more than 50%
of the all nosocomial blood stream infections were due to
gram-negative bacilli. This study also disclosed a pattern
of blood stream infections (BSIs) in Brazilian hospitals
considerably different from the American experience with
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a very high proportion of aerobic gram-negative bacteria
(19). Similarly, Apostolopoulou et al. reported the 4 most
frequently isolated pathogens, A. baumannii (47%), K.
pneumoniae (19.8%), P. aeruginosa (12.6%), and Candida
spp. (7.5%), from Greece (20). Candevir et al. from
Turkey reported a CLABSI rate of 9.14 per 1000 central
catheter days and the most common infecting organism
was A. baumanni (21). CLABSIs caused by A. baumannii
often occur in critically ill, immunosuppressed, highly
antimicrobial agent-experienced patients (4).
Resistance to antimicrobials as a worldwide concern
has a constant trend to increase. Microbiological resistance
profiles revealed MRSA as 66.7%, K. pneumoniae as 54.5%
ESBL, and A. baumannii isolates represented MDR 100%.
XDR of 86.6%, along with carbapenem resistance that
was 91% in A. baumannii, displayed very high resistance
rates in our study compared to NHSN results (22). NHSN
published 2009–2010 data about CLABSI resistance that
was tremendously increasing (MRSA as 54.6%, ESBL
in K. pneumoniae as 28.8%, resistance to carbapenems
in A. baumannii as 62.6% and MDR as 67.6%). This
report suggested that the problem of highly resistant
gram-negative bacteria causing healthcare-associated
infections is not limited to just a small subset of hospitals.
In addition, it reinforced the need for prevention efforts
designed to prevent the further emergence and spread of
these pathogens (22). Deliberato et al. reported very high
rates of resistance to carbapenems by nonfermentative
gram-negative bacteria, higher mortality rates, and a shift
to nonalbicans species of Candida (19). Our alarming
results along with NHSN data represent the urgent need
to take preventive measures for further transmission
(22). Therefore, it is essential to use the antibiotics in
appropriate indications and improve the immune state of
patients for contribution to the prevention of multidrugresistant pathogens and fungi-related BSIs.
Several factors influence mortality rates like causative
microorganism, patient’s general status, and severity of
the disease. Olaechea indicated the variables affecting
mortality in patients in ICUs. In addition to other
variables, the authors reported in that study that fungi
have higher mortality risk compared to bacteria (7). Until
recently, Candida infections emerged mainly in patients
with malignant diseases and in those who underwent
organ transplantation. However, opportunistic fungal
infections have dramatically increased in patients in ICUs
(23) and invasive candidiasis is now an important and
serious infective complication for patients managed in the
ICU (24). Lundberg et al. found candidemia and APACHE
II scores as an independent predictor of mortality in
their study (25). The prognosis of critically ill patients
with invasive candidiasis or candidemia is dreadful, with
mortality rates frequently exceeding 40% (26). Besides
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our higher rate of 68.5% of mortality in patients with
candidiasis, Falagas et al. reported a systematic review of
matched cohort studies in which the attributable mortality
rates ranged from a nonsignificant 5% to a dramatic 71%,
with six out of seven studies finding significantly higher
mortality among case patients (27). Likewise, the results
of the Extended Prevalence of Infection in the ICU Study
(EPIC II), a multicenter study, revealed that of the 14,414
patients 99 patients had Candida BSIs with a prevalence
of 6.9 per 1000 patients. Patients with Candida BSIs,
compared with patients with gram-positive and gramnegative BSIs, had the greatest crude intensive care unit
mortality rates (42.6%, 25.3%, and 29.1%, respectively)
(28). We noted that, of the patients, 86 (54.4%) survived
whereas 72 (45.6%) died. Of 35 the patients with Candida
infection, 24 died (68.5%) (P < 0.01), which indicated that
patients having Candida infection have a significantly
higher mortality rate. APACHE II level and Candida
infections were found to be risk factors for mortality
(mean 25 ± 8). APACHE II, which is inevitably a higher
score in our study, deteriorated patient-factor survival.
In searching for clues for the higher mortality rates in
Candida infections and changing epidemiology of invasive
mycoses, some authors suggested that the prolonged stay
in the ICU was a factor (23), while others implicated
that the CVC removal (29) or the underlying disease
acuity, prevention, and prophylaxis in high-risk patients
was an issue (23). Singh reported a brief and adequate
explanation as to how the frequency of opportunistic
fungal infections has increased. The increasing number
of susceptible hosts, the introduction of newer modalities
for hematopoietic stem cell transplantation, the evolution
of organ transplantation practices, the use of novel
immunosuppressive agents, and the current antimicrobial
prophylactic strategies were reported to likely contribute
to the changing epidemiology of invasive mycoses (30).
Thus, prevention and prophylaxis in high-risk patients
may reduce the occurrence of invasive candidiasis (IC).
However, studies addressing this issue do not directly
indicate the problem of treatment delays when fungal
BSIs occur (31). At this point, authors seemed not to have
a strategy whether a targeted prophylaxis would be more
useful than one of preemptive or early empirical therapy
of infections documented before they produce clinical
signs and symptoms or positive cultures (32). Although
the latter strategy may be more appealing, Pfaller et al.
reported that it was hindered by the lack of truly robust
surrogate markers or nonculture-based methods for early
detection of IC. Such methods are actively being developed
but as yet are not widely available (23).
In conclusion, replacement by gram-negative
microorganisms and fungal infections seems to continue
and this shift may have a major role in mortality rates.
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We found that, the most powerful predictors of mortality
were APACHE II scores and BSI with Candida species.
As the changing microbial spectrum considered, Candida

infections must increasingly be kept in mind not only
for invasiveness but also as a leading causative agent for
mortality.
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